QNZ 46

Pricing Availability   Qty
Description: Non-competitive and GluN2C/GluN2D-selective NMDA antagonist
Chemical Name: 4-[6-Methoxy-2-[(1E)-2-(3-nitrophenyl)ethenyl]-4-oxo-3(4H)quinazolinyl]benzoic acid
Purity: ≥98% (HPLC)
Datasheet
Citations (2)
Reviews
Literature (5)

Biological Activity for QNZ 46

QNZ 46 is a GluN2C/GluN2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for GluN2D, GluN2C, GluN2A, GluN2B, and GluR1, respectively). Requires binding of glutamate to the GluN2 subunit.

Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

Compound Libraries for QNZ 46

QNZ 46 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for QNZ 46

M. Wt 443.41
Formula C24H17N3O6
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 1237744-13-6
PubChem ID 46861929
InChI Key GNLVJIICVWDSNI-LFYBBSHMSA-N
Smiles O=C2C1=CC(OC)=CC=C1N=C(/C=C/C4=CC([N+]([O-])=O)=CC=C4)N2C3=CC=C(C(O)=O)C=C3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for QNZ 46

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 4.43 10 with gentle warming

Preparing Stock Solutions for QNZ 46

The following data is based on the product molecular weight 443.41. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 22.55 mL 112.76 mL 225.52 mL
0.5 mM 4.51 mL 22.55 mL 45.1 mL
1 mM 2.26 mL 11.28 mL 22.55 mL
5 mM 0.45 mL 2.26 mL 4.51 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for QNZ 46

References are publications that support the biological activity of the product.

Mosley et al (2010) Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-MthD.-aspartate receptor antagonists. J.Med.Chem. 53 5476 PMID: 20684595

Hansen and Traynelis (2011) Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J.Neurosci. 31 3650 PMID: 21389220


If you know of a relevant reference for QNZ 46, please let us know.

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: QNZ 46, QNZ 46 supplier, QNZ46, Glu, NR2C, NR2D, antagonists, glutamate, NMDA, receptors, GluN2C, GluN2D, Receptors, 4801, Tocris Bioscience

2 Citations for QNZ 46

Citations are publications that use Tocris products. Selected citations for QNZ 46 include:

Brancaccio et al (2017) Astrocytes Control Circadian Timekeeping in the Suprachiasmatic Nucleus via Glutamatergic Signaling. Neuron 93 1420 PMID: 28285822

Robert H et al (2020) Astrocytes Are Required for Oligodendrocyte Survival and Maintenance of Myelin Compaction and Integrity. Front Cell Neurosci 14 74 PMID: 32300294


Do you know of a great paper that uses QNZ 46 from Tocris? Please let us know.

Reviews for QNZ 46

There are currently no reviews for this product. Be the first to review QNZ 46 and earn rewards!

Have you used QNZ 46?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.